Purple Biotech

Purple Biotech is a dynamic biotechnology research company dedicated to pioneering first-in-class therapies aimed at significantly improving treatment outcomes for cancer patients. Purple Biotech's innovative approach focuses on overcoming tumor immune evasion and drug resistance, positioning it as a key player in the future of oncology treatments. The company’s oncology pipeline features promising therapies like NT219, CM24, and IM1240, each designed with unique mechanisms to combat cancer effectively.

Located at Oppenheimer 4, Rehovot, 7670104, IL, Purple Biotech is committed to advancing medical science through rigorous clinical trials and strategic collaborations. The company is actively involved in Phase 1/2 studies for NT219, exploring its potential as a monotherapy for solid tumors and in combination with cetuximab for treating recurrent and metastatic squamous cell carcinoma of the head and neck (SCCHN) or colorectal adenocarcinoma (CRC). Furthermore, CM24 is being developed as a combination therapy with anti-PD-1 checkpoint inhibitors in a Phase 2 study for pancreatic ductal adenocarcinoma (PDAC), showcasing Purple Biotech's dedication to innovative treatment strategies.

Purple Biotech's dedication to innovation and patient outcomes drives its mission to develop groundbreaking therapies that transform cancer treatment. With a strong pipeline and a clear vision for the future, Purple Biotech is poised to make a significant impact on the landscape of oncology. We invite the management team at Purple Biotech to enhance your company's visibility by creating a customized and exclusive company showcase and product listing on our platform, further amplifying your reach and potential.